

NA Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 193 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The North America melanoma cancer diagnostics market is projected to register a substantial CAGR of 7.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Melanoma Cancer Diagnostics Market, By Product Type (Instruments, Consumables and Accessories, and Others), Test Type (Biomarkers Test, Imaging Test, Biopsy, Fluorescent In Situ Hybridization (FISH) Tests, Comparative Genomic Hybridization (CGH) tests, Immunohistochemical (IHC) tests, and Others), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), Distribution channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast 2030

Some of the major factors contributing to the growth of the North America melanoma cancer diagnostics market are:

- Increase in demand for early melanoma diagnosis
- Rising preference for preventive health check-ups

Market Players:

Some of the major players operating in the North America melanoma cancer diagnostics market are:

- NanoString
- Thermo Fisher Scientific Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
- QIAGEN
- Inivata Ltd.
- F. Hoffman-La Roche Ltd
- Abbott
- Myriad Genetics, Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Castle Biosciences
- DermTech
- Michael Diagnostics Ltd
- DermLite
- DermaSensor
- Skyline Dx
- VERISKIN INC.
- Illumina Inc
- bioMerieux SA

Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION	48
1.1 OBJECTIVES OF THE STUDY	48
1.2 MARKET DEFINITION	48
1.3 OVERVIEW OF THE NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET	48
1.4 LIMITATIONS	50
1.5 MARKETS COVERED	50
2 MARKET SEGMENTATION	53
2.1 MARKETS COVERED	53
2.2 GEOGRAPHICAL SCOPE	54
2.3 YEARS CONSIDERED FOR THE STUDY	55
2.4 CURRENCY AND PRICING	55
2.5 DBMR TRIPOD DATA VALIDATION MODEL	56
2.6 MULTIVARIATE MODELLING	60
2.7 PRODUCT TYPE LIFELINE CURVE	60
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	61
2.9 DBMR MARKET POSITION GRID	62
2.10 MARKET END USER COVERAGE GRID	63
2.11 VENDOR SHARE ANALYSIS	64
2.12 SECONDARY SOURCES	65
2.13 ASSUMPTIONS	65
3 EXECUTIVE SUMMARY	66
4 PREMIUM INSIGHTS	68
4.1 PESTEL'S MODEL	69
4.2 PORTER'S FIVE FORCES MODEL	70
5 EPIDEMIOLOGY	71
6 INDUSTRY INSIGHTS	72
6.1 DEMOGRAPHIC TRENDS	72
6.2 KEY PRICING STRATEGIES	73
6.2.1 PRODUCT INNOVATION	73
6.2.2 CONSUMER AWARENESS	73
6.2.3 A VAST NETWORK OF DISTRIBUTION	73
6.2.4 PARTNERSHIP WITH POPULAR BRANDS BY MAJOR PLAYERS	74
6.2.5 OTHERS	74

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3 KEY PATIENT ENROLLMENT STRATEGIES	74
6.3.1 IDENTIFICATION OF CUSTOMERS NEED FOR INNOVATIVE DIAGNOSTIC PRODUCTS	74
6.3.2 INCREASING SPECIFIC TACTICS FOR EVERY STEP	74
6.3.3 EDUCATE AND COMMUNICATE	75
6.3.4 IMPROVING DIAGNOSIS SEEKING RATE	75
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES	75
7 MARKET OVERVIEW	77
7.1 DRIVERS	79
7.1.1 GROWING PREVALENCE OF MELANOMA CANCER	79
7.1.2 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	80
7.1.3 NOVEL TECHNOLOGIES IN MELANOMA CANCER DIAGNOSTICS	81
7.1.4 INCREASING AWARENESS REGARDING MELANOMA CANCER	82
7.2 RESTRAINTS	82
7.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS	82
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR MELANOMA CANCERS	83
7.3 OPPORTUNITIES	83
7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR MELANOMA CANCER TREATMENT	83
7.3.2 GOVERNMENT INITIATIVES TOWARD MELANOMA CANCER DIAGNOSTICS	84
7.3.3 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS	85
7.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE	85
7.4 CHALLENGES	86
7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF MELANOMA CANCER DIAGNOSTIC PRODUCTS	86
7.4.2 RADIATION RISKS FROM IMAGING TESTS	86
8 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE	87
8.1 OVERVIEW	88
8.2 INSTRUMENTS	91
8.2.1 IMAGING INSTRUMENTS	92
8.2.1.1 ULTRASOUND SYSTEMS	92
8.2.1.2 MRI SYSTEMS	92
8.2.1.3 CT SYSTEMS	92
8.2.1.4 OTHERS	93
8.2.2 BIOPSY INSTRUMENTS	93
8.2.3 PATHOLOGY-BASED INSTRUMENTS	93
8.2.3.1 PCR INSTRUMENTS	93
8.2.3.2 CELL PROCESSORS	93
8.2.3.3 SLIDE STAINING SYSTEMS	93
8.2.3.4 TISSUE PROCESSING SYSTEMS	94
8.2.3.5 OTHER PATHOLOGY-BASED INSTRUMENTS	94
8.3 CONSUMABLES & ACCESSORIES	94
8.3.1 KITS	95
8.3.1.1 PCR KITS	95
8.3.1.2 NUCLEIC ACID ISOLATION KITS	95
8.3.1.3 DNA POLYMERASE KITS	95
8.3.1.4 OTHERS	96
8.3.2 PROBES	96
8.3.2.1 Q FISH	96

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3.2.2 FLOW FISH	96
8.3.2.3 OTHERS	96
8.3.3 REAGENTS	96
8.3.3.1 ASSAYS	97
8.3.3.2 BUFFERS	97
8.3.3.3 PRIMERS	97
8.3.3.4 OTHERS	97
8.3.4 OTHER CONSUMABLES	97
8.4 OTHERS	97
9 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY TEST TYPE	99
9.1 OVERVIEW	100
9.2 IMAGING TEST	103
9.2.1 ULTRASOUND	104
9.2.2 MRI	104
9.2.3 CHEST X-RAY	104
9.2.4 LYMPHOSCINTIGRAPHY	105
9.2.5 COMPUTED TOMOGRAPHY (CT) SCAN	105
9.2.6 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	105
9.2.7 OTHERS	105
9.3 BIOPSY	105
9.3.1 OPTICAL BIOPSY	106
9.3.2 EXCISIONAL BIOPSY	106
9.3.3 INCISIONAL BIOPSY	106
9.3.4 SHAVE BIOPSY	107
9.3.5 PUNCH BIOPSY	107
9.3.6 OTHERS	107
9.4 IMMUNOHISTOCHEMICAL (IHC) TESTS	107
9.4.1 S100 PROTEIN FAMILY BIOPSY	108
9.4.2 MELAN-A	108
9.4.3 PMEL/PMEL17/SILV/GP100	108
9.4.4 TYROSINASE	108
9.4.5 MITF	108
9.4.6 SM5-1	108
9.4.7 CSPG4/HMW-MAA	108
9.5 BIOMARKER TEST	109
9.5.1 BRAF MUTATION TEST	110
9.5.2 NRAS MUTATION TEST	110
9.5.3 CKIT TEST	110
9.5.4 OTHERS	110
9.6 FLUORESCENT IN SITU HYBRIDIZATION (FISH) TESTS	110
9.7 COMPARATIVE GENOMIC HYBRIDIZATION (CGH) TESTS	111
9.8 OTHERS	112
10 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY END USER	113
10.1 OVERVIEW	114
10.2 HOSPITALS	117
10.3 ASSOCIATED LABS	118
10.4 DIAGNOSTIC IMAGING CENTERS	118

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.5 INDEPENDENT DIAGNOSTIC LABORATORIES	119
10.6 CANCER RESEARCH INSTITUTES	120
10.7 OTHERS	121
11 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	122
11.1 OVERVIEW	123
11.2 DIRECT TENDER	126
11.3 RETAIL SALES	126
12 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, BY REGION	128
12.1 NORTH AMERICA	129
12.1.1 U.S.	139
12.1.2 CANADA	144
12.1.3 MEXICO	149
13 NORTH AMERICA MELANOMA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	154
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	154
14 SWOT ANALYSIS	155
15 COMPANY PROFILE	156
15.1 ABBOTT	156
15.1.1 COMPANY SNAPSHOT	156
15.1.2 REVENUE ANALYSIS	156
15.1.3 COMPANY SHARE ANALYSIS	157
15.1.4 PRODUCT PORTFOLIO	157
15.1.5 RECENT DEVELOPMENTS	157
15.2 ILLUMINA, INC.	158
15.2.1 COMPANY SNAPSHOT	158
15.2.2 REVENUE ANALYSIS	158
15.2.3 COMPANY SHARE ANALYSIS	159
15.2.4 PRODUCT PORTFOLIO	159
15.2.5 RECENT DEVELOPMENT	159
15.3 BIOMERIEUX SA	160
15.3.1 COMPANY SNAPSHOT	160
15.3.2 REVENUE ANALYSIS	160
15.3.3 COMPANY SHARE ANALYSIS	161
15.3.4 PRODUCT PORTFOLIO	161
15.3.5 RECENT DEVELOPMENTS	161
15.4 THERMO FISHER SCIENTIFIC INC.	162
15.4.1 COMPANY SNAPSHOT	162
15.4.2 REVENUE ANALYSIS	162
15.4.3 COMPANY SHARE ANALYSIS	163
15.4.4 PRODUCT PORTFOLIO	163
15.4.5 RECENT DEVELOPMENT	163
15.5 F. HOFFMANN-LA ROCHE LTD.	164
15.5.1 COMPANY SNAPSHOT	164
15.5.2 REVENUE ANALYSIS	164
15.5.3 COMPANY SHARE ANALYSIS	165
15.5.4 PRODUCT PORTFOLIO	165
15.5.5 RECENT DEVELOPMENT	165
15.6 AGILENT TECHNOLOGIES, INC.	166

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.6.1 COMPANY PROFILE	166
15.6.2 REVENUE ANALYSIS	166
15.6.3 PRODUCT PORTFOLIO	167
15.6.4 RECENT DEVELOPMENT	167
15.7 AMLO BIOSCIENCES LIMITED	168
15.7.1 COMPANY PROFILE	168
15.7.2 PRODUCT PORTFOLIO	168
15.7.3 RECENT DEVELOPMENT	168
15.8 CASTLE BIOSCIENCES INC	169
15.8.1 COMPANY SNAPSHOT	169
15.8.2 REVENUE ANALYSIS	169
15.8.3 PRODUCT PORTFOLIO	170
15.8.4 RECENT DEVELOPMENT	170
15.9 DAMAE MEDICAL	171
15.9.1 COMPANY PROFILE	171
15.9.2 PRODUCT PORTFOLIO	171
15.9.3 RECENT DEVELOPMENT	171
15.10 DERMLITE.	172
15.10.1 COMPANY PROFILE	172
15.10.2 PRODUCT PORTFOLIO	172
15.10.3 RECENT DEVELOPMENTS	172
15.11 DERMASENSOR	173
15.11.1 COMPANY PROFILE	173
15.11.2 PRODUCT PORTFOLIO	173
15.11.3 RECENT DEVELOPMENT	173
15.12 DERMTECH	174
15.12.1 COMPANY SNAPSHOT	174
15.12.2 REVENUE ANALYSIS	174
15.12.3 PRODUCT PORTFOLIO	175
15.12.4 RECENT DEVELOPMENT	175
15.13 INIVATA LTD.	176
15.13.1 COMPANY PROFILE	176
15.13.2 PRODUCT PORTFOLIO	176
15.13.3 RECENT DEVELOPMENT	176
15.14 MICHAEL DIAGNOSTICS LTD	177
15.14.1 COMPANY SNAPSHOT	177
15.14.2 PRODUCT PORTFOLIO	177
15.14.3 RECENT DEVELOPMENT	177
15.15 MYRIAD GENETICS, INC.	178
15.15.1 COMPANY SNAPSHOT	178
15.15.2 REVENUE ANALYSIS	178
15.15.3 PRODUCT PORTFOLIO	179
15.15.4 RECENT DEVELOPMENT	179
15.16 NANOSTRING	180
15.16.1 COMPANY SNAPSHOT	180
15.16.2 REVENUE ANALYSIS	180
15.16.3 PRODUCT PORTFOLIO	181

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.16.4 RECENT DEVELOPMENT	181
15.17 NERACARE GMBH	182
15.17.1 COMPANY PROFILE	182
15.17.2 PRODUCT PORTFOLIO	182
15.17.3 RECENT DEVELOPMENT	182
15.18 SKIN ANALYTICS	183
15.18.1 COMPANY PROFILE	183
15.18.2 PRODUCT PORTFOLIO	183
15.18.3 RECENT DEVELOPMENT	183
15.19 SKYLINEDX	184
15.19.1 COMPANY PROFILE	184
15.19.2 PRODUCT PORTFOLIO	184
15.19.3 RECENT DEVELOPMENTS	184
15.20 VERISKIN INC.	185
15.20.1 COMPANY PROFILE	185
15.20.2 PRODUCT PORTFOLIO	185
15.20.3 RECENT DEVELOPMENTS	185
15.21 QIAGEN	186
15.21.1 COMPANY SNAPSHOT	186
15.21.2 REVENUE ANALYSIS	186
15.21.3 PRODUCT PORTFOLIO	187
15.21.4 RECENT DEVELOPMENT	187
15.22 QUEST DIAGNOSTICS INCORPORATED (2022)	188
15.22.1 COMPANY SNAPSHOT	188
15.22.2 REVENUE ANALYSIS	188
15.22.3 PRODUCT PORTFOLIO	189
15.22.4 RECENT DEVELOPMENTS	189
16 QUESTIONNAIRE	190
17 RELATED REPORTS	193

NA Melanoma Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 193 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com